Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Management Strategy & Planning Division Corporate Planning
Telephone: 03-3525-4707

Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent “Lasvic® Tablets 75mg”

TOKYO, Japan (September 20, 2019) —Kyorin Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Shigeru Ogihara), a wholly owned subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 20, 2019 to market the oral quinolone antibacterial drug Lasvic® Tablets 75mg.

Lasvic® Tablets 75mg are a novel quinolone antibacterial drug manufactured by Kyorin Pharmaceutical Co., Ltd. as a new treatment for respiratory and ENT infections. This drug has strong antibacterial activity against the primary causative bacteria of community-acquired respiratory infections and also exhibits good activity against streptococci and anaerobic bacteria in the oral cavity, which have attracted attention recently as the causative bacterial of community-acquired pneumonia. Meanwhile, its penetration to the tissue of the lungs, ear, nose and throat is good and, even at small doses, it maintains an effective drug concentration in infected tissue and demonstrates a high level of therapeutic effectiveness.

Currently, Japan faces the problem that research and development of new antibacterial agents is slow moving amid efforts to prevent overuse of antimicrobial drugs with a view to addressing the issue of antimicrobial resistance (AMR). Under such conditions, we succeeded in developing this drug by focusing on research based on the idea that it is befitting for antibacterial drugs in the future that we maintain the high level of therapeutic effectiveness of quinoline drugs against respiratory and ENT infections while reducing their side effects and the risk of emergence of resistant bacteria.

Kyorin Pharmaceutical Co., Ltd. aims to further contribute to the treatment of patients by adding Lasvic® Tablets to its product lineup in the respiratory field, which one of its priority fields, and by providing up-to-date information on an ongoing basis.

Further details, including the timing of release and projected sales, will be announced in a timely manner after this drug has been listed on the National Health Insurance drug price list.
Brand name : Lasvic® Tablets 75mg
Generic name : Lascufloxacin Hydrochloride
INN : LSFX

Indications:
<Bacterial strains> The genus Staphylococcus, the genus Streptococcus, Pneumococcus, Moraxella (Branhamella) Catarrhalis, the genus Klebsiella, the genus Enterobacter, Haemophilus Influenzae, Legionella Pneumophila, the genus Prevotella and Mycoplasma Pneumoniae that are sensitive to this drug
<Diseases> Pharyngitis, stomatitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, middle ear infection, sinusitis

Dosage and Administration: The usual oral dosage for adults is 75mg of lascufloxacin once daily.